Iron chelator in patients with sickle cell anemia : comparative study

Abstract EN

Background : the two main reasons for blood transfusion in sickle cell disease are to correct anemia so that the oxygen-carrying capacity of the blood is improved, and to treat or prevent painfulvasoocclusiveby lowering the proportion of sickle cell hemoglobin.

Iron over load will be evitable.

Aim : The aim of this study is to assessafety and efficiency of different chelation therapy.

Patients and method : Fifty two patients divided in to two equal group, for treatment by combined Deferoxamine-Deferasirox therapy and on Deferasirox alone.

Results : both drug regimens proved to have no adverse effect on hepatic or renal function.

The degree of descend of serum ferritin is significantly higher with combined Deferoxamine-Deferasirox therapy.

Conclusion : combined chelating agents have significant effect on serum ferritin, with acceptable level of safety.

Recommendation : combined therapy was safe regime and can be used with good efficacy for patients with iron over load.